Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal

Proposed $20m funding boost for rare disease development includes review of orphan incentives, including how to potentially stimulate development in ultra-orphan diseases.

FDAEntrance_1200x675

A review of potential ultra-orphan incentives in the US FDA's fiscal year 2019 budget request may signal a change in its approach to the space.

The agency requested an additional $20m for "stimulating medical product development for rare diseases" in its FY 2019 budget...

More from Rare Diseases

More from Pink Sheet